Rapid responses are electronic comments to the editor. They enable our users to debate issues raised in articles published on bmj.com. A rapid response is first posted online. If you need the URL (web address) of an individual response, simply click on the response headline and copy the URL from the browser window. A proportion of responses will, after editing, be published online and in the print journal as letters, which are indexed in PubMed. Rapid responses are not indexed in PubMed and they are not journal articles. The BMJ reserves the right to remove responses which are being wilfully misrepresented as published articles.
We are very astonished by the aplomb of the paper by Weber et al (1)
emphasizing the fact that Tamiflu use within the first 48 hours of swine
flu is efficacy sound. A number of reports in Australia (2), Australia and
New Zealand (3), United Sates of America (4) and England (5) have
suggested this efficacy but unfortunately controlled studies are lacking.
We cannot believe that post hoc statistic analysis like multivariate ones
are robust and pertinent to state that Tamiflu is effective. Moreover, we
are sure that independent controlled studies are not planned regarding
Tamiflu efficacy in severe acute respiratory symptoms or in so-called at
risks groups: we are always waiting for such studies in seasonal flu.
Finally we can consider that experts’ advice on Tamiflu has the same
relevance as experts’ predictions of the number of deaths due to the